RXO Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of RXO Inc.

Kahn Swick & Foti and former Louisiana Attorney General Charles C. Foti Jr. are investigating RXO’s proposed sale to C.H. Robinson. Under the announced terms, RXO shareholders would receive $17.25 in cash and 0.0856 shares of C.H. Robinson common stock for each RXO share; the article provides no investigation findings or additional transaction details.

Analysis

The investigation headline is not, by itself, evidence that the transaction is impaired: no specific alleged defect, filed complaint, or requested remedy is provided. The immediate risk is therefore more likely a modest widening in RXO’s deal spread than a fundamental change in either company’s earnings outlook. The meaningful catalyst is whether the inquiry becomes litigation that delays a vote or closing, or produces a change in deal terms; timing and probability cannot be assessed from this release alone.

For a merger-arbitrage framework, the stated stock component implies a hedge of 0.0856 CHRW shares short per RXO share long, with the cash component left unhedged. This reduces consideration-value exposure to CHRW while the deal remains live, but does not hedge the downside if the transaction breaks: RXO could reprice independently and the CHRW short would remain. Do not treat the law firm’s investigation announcement as proof of shareholder harm or as a reliable forecast of litigation outcome.

Over 1–3 months, monitor any actual complaint, court action, shareholder-vote developments, and company disclosures on timing or terms. Over 6–18 months, the broader competitive question is whether combining the businesses yields durable operating efficiencies or integration costs; the supplied information does not establish either. Missing inputs before sizing a trade include current RXO price, CHRW price, implied deal spread, closing timeline, termination provisions, and any formal legal filing.

Key Decisions for Investors

• No directional trade on this headline alone. First calculate the current deal spread using RXO’s price and the cash-plus-stock consideration; compare it with a realistic break-price scenario and expected time to close.
• If the spread offers adequate compensation, consider a sized long RXO / short 0.0856 CHRW shares per RXO share position. Treat it as event risk, not a risk-free hedge; cap exposure for the potentially asymmetric break downside.
• Escalate the risk assessment only if the inquiry becomes a filed suit, seeks an injunction or material change in terms, or is accompanied by a vote or closing delay. Reassess immediately if either company discloses a revised timeline or transaction terms.
• Falsify the low-impact view if formal proceedings materially threaten closing or the implied spread widens beyond the fund’s break-risk tolerance; absent those developments, avoid paying for protection against a routine investigation announcement.